BTIG Research Reiterates Buy Rating for OrthoPediatrics (NASDAQ:KIDS)

OrthoPediatrics (NASDAQ:KIDS)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $23.00 price target on the stock. BTIG Research’s price objective suggests a potential upside of 39.65% from the company’s current price.

Other analysts have also recently issued reports about the company. Citigroup reissued an “outperform” rating on shares of OrthoPediatrics in a research report on Friday, October 10th. Stifel Nicolaus decreased their target price on OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, October 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Wednesday, October 8th. Truist Financial set a $18.00 price target on OrthoPediatrics in a report on Friday, October 10th. Finally, Piper Sandler lowered their price target on OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, OrthoPediatrics has an average rating of “Moderate Buy” and an average price target of $24.00.

OrthoPediatrics Stock Performance

NASDAQ:KIDS opened at $16.47 on Wednesday. The firm has a market capitalization of $412.97 million, a PE ratio of -8.45 and a beta of 1.02. The business’s fifty day moving average price is $18.93 and its 200 day moving average price is $20.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. OrthoPediatrics has a 12 month low of $15.28 and a 12 month high of $32.00.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Monday, January 9th. The company reported ($0.15) EPS for the quarter. The business had revenue of $25.08 million during the quarter. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.85%. On average, sell-side analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Fred Hite acquired 5,076 shares of the company’s stock in a transaction that occurred on Thursday, August 21st. The stock was purchased at an average cost of $19.41 per share, with a total value of $98,525.16. Following the purchase, the chief financial officer directly owned 213,065 shares of the company’s stock, valued at approximately $4,135,591.65. This trade represents a 2.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 32.70% of the stock is owned by insiders.

Institutional Trading of OrthoPediatrics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Brown Advisory Inc. lifted its stake in shares of OrthoPediatrics by 6.2% during the 1st quarter. Brown Advisory Inc. now owns 1,628,747 shares of the company’s stock worth $40,116,000 after purchasing an additional 94,719 shares during the period. Vanguard Group Inc. increased its holdings in shares of OrthoPediatrics by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 937,969 shares of the company’s stock worth $23,102,000 after buying an additional 14,079 shares during the last quarter. Millennium Management LLC boosted its position in OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock worth $16,172,000 after purchasing an additional 233,873 shares during the period. AWM Investment Company Inc. boosted its position in OrthoPediatrics by 5.5% during the 1st quarter. AWM Investment Company Inc. now owns 545,282 shares of the company’s stock worth $13,430,000 after purchasing an additional 28,488 shares during the period. Finally, Marshall Wace LLP boosted its position in OrthoPediatrics by 17.8% during the 2nd quarter. Marshall Wace LLP now owns 419,129 shares of the company’s stock worth $9,003,000 after purchasing an additional 63,345 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.